Kaitlyn D’Onofrio

DocwireNews

Researchers recently assessed the safety and efficacy of sarilumab either as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with varying severities of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/tofacitinib-baricitinib-upadacitinib-filgotinib-or-peficitinib-study-compares-five-rheumatoid-arthritis-monotherapies/">rheumatoid arthritis</a> (RA).&ldquo;Characterization of subpopulations of patients most likely to respond favourably or unfavourably to conventional synthetic disease-modifying <a href="https://www.docwirenews.com/docwire-pick/study-predictors-tofacitinib-success/">antirheumatic</a> drugs (csDMARDs) and/or biologic DMARDs (bDMARDs) could help guide appropriate use of the many therapies now available and improve patient outcomes,&rdquo; the researchers explained.To perform their analysis, researchers gathered data from phase 3 studies. This included two placebo-controlled trials of subcutaneous sarilumab 150 mg or 200 mg every two weeks (Q2W) in combination with either methotrexate in patients with an inadequate response to <a href="https://www.docwirenews.com/docwire-pick/etanercept-methotrexate-alone-arthritis/">methotrexate</a> alone (52 weeks) or csDMARDs in patients who had an inadequate response or intolerance to <a href="https://www.docwirenews.com/docwire-pick/tofacitinib-vte-risk-tnf-inhibitors/">tumor necrosis factor inhibitors</a>, and one of sarilumab 200 mg Q2W as monotherapy compared to adalimumab 40 mg Q2W in patients who had an inadequate response or intolerance to methotrexate (24 weeks). Patients were assessed by demographics, disease characteristics, and prior treatments. Clinical, radiographic, and physical function measures were all assessed as outcomes.Overall, sarilumab was clinically superior as a monotherapy compared to adalimumab as well as in combination with csDMARDs compared to placebo plus csDMARDs across all patient demographic, disease characteristics, and prior treatments subgroups.&ldquo;Interaction&nbsp;p&nbsp;values of &lt;&thinsp;0.05 were consistently observed across studies only for baseline anti-cyclic citrullinated peptide antibody (ACPA) status for American College of Rheumatology 20% response, but not American College of Rheumatology 50% or 70% response,&rdquo; the study authors did note.Patients taking sarilumab, compared to those taking placebo, were more likely to experience adverse events and worsening laboratory parameters, as well as patients aged &ge;65&thinsp;years&mdash;which the authors noted was a small population of the study (n=289) compared to patients aged &lt;65 years (n=1,819). Six patients aged &ge;65&thinsp;years experienced serious infections; however, patients aged &ge;65&thinsp;years in all treatment groups were more likely to sustain serious infections.The study was published in <a href="https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02194-z">Arthritis Research &amp; Therapy</a>.&ldquo;These data suggest that treatment with sarilumab is associated with beneficial effects across a broad spectrum of patients who have RA,&rdquo; the authors summarized.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Sarilumab, Alone or in Combination with Conventional Synthetic DMARDs, Safe and Effective for Most RA Patients

Rheumatoid Arthritis

Researchers recently assessed the safety and efficacy of sarilumab either as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs ...

Sarilumab, Alone or in Combination with Conventional Synthetic DMARDs, Safe and Effective for Most

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe